

A PROSPECTIVE STUDY AND CORRELATION BETWEEN GLYCOSYLATED HAEMOGLOBIN AND SERUM LIPID PROFILE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN KANPUR (UP)

¹Dr. Zuhaib Ali, ²Dr. Sudhir Sharma

¹Assistant Professor, Dept. of Medicine, Naraina Medical College and Research Center, Kanpur

²Assistant Professor, Department of Dermatology, Naraina Medical College and Research Center Kanpur

Corresponding Author: Dr. Zuhaib Ali

Abstract

Introduction: Patients with type 2 diabetes have an increased prevalence of lipid abnormalities, contributing to their high risk of cardiovascular diseases (CVD). This study is an attempt to evaluate the diagnostic value of Glycosylated hemoglobin (HbA1c) in predicting diabetic dyslipidemia.

Aims & Objectives: To study the correlation between glycosylated hemoglobin (HbA1c) and serum lipid profile in Type 2 Diabetics

Material and Methods: This study conducted at Department of General Medicine, Naraina Medical College And Research center from June 2021 to February 2022. In our study 50 patients of Type 2 diabetes mellitus were taken for the study after applying inclusion and exclusion criteria, and after obtaining written and informed consent from them. HbA1c and Fasting Lipid profile were done using appropriate tests. Correlation (Pearson's) test was used to interpret the result

Results: Mean total cholesterol was 155.76 ± 13.41 , mean total triglyceride was 180.52 ± 17.21 , mean LDL was 99.09 ± 12.72 , Mean HDL was 36.94 ± 4.28 and mean HbA1c was 9.76 ± 1.46 . HbA1c negatively and significantly correlated with HDL ($r = -0.13$). HbA1c positively and significantly correlated with total cholesterol ($r = 0.20$) and LDL ($r = 0.24$), did not show any show correlation with VLDL ($r = 0.03$) and total triglycerides ($r = 0.02$).

Conclusion: It was concluded from the results of this study that HbA1c can also be used as predictor of dyslipidaemia in Type 2 Diabetics in addition to as a glycaemic control parameter.

Key words: Type 2 diabetes, Cardiovascular diseases, Glycosylated haemoglobin, Dyslipidaemia.

Introduction

Diabetes mellitus (DM) refers to a bunch of disorders of metabolism that share the phenotypic sign of hyperglycaemia. Different variants of DM are caused due to the interaction of various genetic factors with environmental factors. Depending on the pathogenic process leading to hyperglycaemia DM is classified, as Type I, Type II, Gestational Diabetes and Other specific types as maturity onset diabetes of youth (MODY), lipodystrophy diabetes, secondary diabetes due to pancreatitis, hemochromatosis, drug-induced, infectious, insulin receptor antibodies. ^[1]

Type II diabetes mellitus (T2DM) is a chronic disease that develops due to defective insulin secretion and is frequently associated with insulin resistance.^[2] It is also characterized by progressively decreasing beta-cell function over time.^[3,4] It contributes to about 90- 95 % of all diagnosed cases of DM in adults and currently affects more than 61.3 million Indian people that is more than 8% of the adult population. The age of onset of T2DM is 42.5 years on an average. Diabetes accounts to 1 million deaths in India every year.^[5] The prevalence of dyslipidaemia was 39.9%, 46.8%, and 59.3% in participants with normal glucose, prediabetes, and type 2 diabetes mellitus (T2DM). Women had a lower dyslipidaemia prevalence than men (38.7% vs. 43.3%).^[6] The feature of chronic hyperglycaemia is a forecaster of development of complications associated with diabetes. These can be divided into micro-vascular, macro-vascular and other complications. Micro-vascular complications of diabetes include diabetic neuropathy, diabetic nephropathy and diabetic retinopathy.^[7] The complications of DM categorized under macro-vascular complications include cardiovascular disease, cerebrovascular disease and diseases related to peripheral vessels. Along with these complications, weight gain related with diabetes lead to further worsening of the disease. Other complications include acute metabolic complications, diabetic ketoacidosis.^[8] The most common pattern of abnormality in patients with Type 2 diabetes mellitus is increased triglyceride levels, decreased HDL levels and increased concentration of low – density lipoproteins (LDL) particles. These LDL particles have been identified as a major risk factor for chronic heart disease (CHD) by the National Cholesterol Education Programme (NCEP) Adult Treatment panel (ATP) III. It has been shown that reducing the plasma LDL cholesterol levels sharply reduces the risk of subsequent clinical Coronary Heart Diseases in both patients with pre-existing Coronary Heart Diseases and in patients free of Coronary Heart Diseases. While LDL cholesterol is a strong risk factor for coronary artery disease (CAD).^[9] Glycosylated haemoglobin (HbA1) is a term used to describe a series of stable minor haemoglobin components formed slowly and non-enzymatically from haemoglobin and glucose.^[10] The glycation of haemoglobin can occur at various sites present on the polypeptide chains of the haemoglobin molecule with different carbohydrate molecules. More recently HbA1c is defined as Hb that is irreversibly glycated at one or both N- terminal valines of the β -chain. The remaining GHbs have glucose, glucose-6-phosphate, fructose-1,6-diphosphate, or pyruvic add bound to one of the 44 additional sites occurring at s-amino group of lysine residues or at the NH₂ terminal of the α -chain.^[11] Formation of HbA1c is irreversible and the blood levels depend on both of the life span of red blood cell (average 120 days) and blood glucose concentration. The rate of formation of HbA1c is directly proportional to the ambient glucose concentration. The amount of HbA1c therefore represents the integrated values of glucose over the last three months and provides an additional means of assessing glycaemic control.^[12] Hence, the study has been planned to evaluate the value of HbA1c as marker of dyslipidaemia in Type 2 Diabetics

Material and Methods:

This study conducted at Department of General Medicine, Naraina Medical College And Research center from June 2021 to February 2022. Total 50 patients of Type 2 diabetes mellitus were taken for the study after applying inclusion and exclusion criteria, and after obtaining written and informed consent from them.

Inclusion criteria

- Adults aged above 30 years and having Type 2 Diabetes Mellitus

Exclusion criteria

- Patients with hypothyroidism, nephrotic syndrome, cholestatic liver disease, chronic kidney disease
- Patients with BMI >30kg/m²
- Patients on lipid lowering drugs
- Patients on OCP's, steroids and thiazide diuretics

HbA1c and Fasting Lipid profile: Total cholesterol, Triglycerides, HDL and VLDL cholesterol were measured using Erba blood analyser were done using appropriate tests.

- LDL cholesterol was calculated using friedwald formula.
- HbA1c was estimated by appropriate standard kits.
- Dyslipidaemia was defined according to NCEP-ATPIII guidelines.

Statistical Analysis:

The data was analysed with SPSS version 25.0. The mean, SD and correlation(Pearson's) test was used to interpret the results. Correlation coefficient ($r \geq +1$ is taken as positive correlation, ≤ -1 is taken as negative correlation and between -1 and $+1$ as no correlation. Correlation (Pearson's) test was used to interpret the result.

Result

In our study, among 50 Type 2 diabetic individuals included in this study, 24 were male and 26 were female.

Table 1: Sex Distribution of study population

	Total	Males	Females
No. of patients	50	24	26
Percentage	100	48	52
Chi-Square test p=	0.112		

Table 2: Lipid profile of study population based on gender

Lipid profile	Total	Male	Female
Hypercholesterolemia	9	4	5
Hypertriglyceridemia	26	10	16
Low HDL	28	13	15
High LDL	21	10	11
No abnormality	6	4	2

In table 2, lipid profiles were taken into consideration, 9 patients had TC levels > 200 mg/dl, 26 patients had TG levels > 150 mg/dl, 28 patients had LDL levels > 100 mg/dl and 21 patients had HDL levels < 40 mg/dl.

Table 3: Distribution of Lipid Profile and HbA1c

Parameters	Mean \pm SD
Mean HbA1c	9.76 \pm 1.46
Mean Total cholesterol	155.76 \pm 13.41
Mean Triglycerides	180.52 \pm 17.21
Mean HDL	36.94 \pm 4.28
Mean LDL	99.09 \pm 12.72

In table 3, Mean total cholesterol was 155.76 ± 13.41 , mean total triglyceride was 180.52 ± 17.21 , mean LDL was 99.09 ± 12.72 , Mean HDL was 36.94 ± 4.28 and mean HbA1c was 9.76 ± 1.46 .

Table 4: correlation analysis between serum Lipid profile and HbA1c.

Parameters	Correlation coefficient (r)	p - value
Total cholesterol-HbA1c	0.207	0.021
Triglyceride-HbA1c	0.028	0.432
HDL-HbA1c	- 0.130	0.032
LDL-HbA1c	0.241	0.041
VLDL-HbA1c	0.031	0.589

In our study table 4, HbA1c positively and significantly correlated with total cholesterol ($r=0.20$), LDL ($r=0.24$), HbA1c negatively and significantly correlated with HDL ($r= - 0.13$), and did not show any show correlation with VLDL ($r=0.03$) and total triglycerides ($r=0.02$).




Figure 1: Lipid parameters categorized by patient's glycaemic control (HbA1c)




Figure 2: Correlations between HbA1c and Lipid Profile Parameters.

Discussion

In the present study, we have evaluated the pattern of lipid profile parameters in diabetic subjects and its correlation with HbA1c. This study demonstrates the typical dyslipidaemia in diabetics characterized by high triglyceride, low HDL. Although there was no significant difference between male and female, the levels of TC and LDL were significantly higher in female as compared to male Type 2 diabetic patients. This finding is in agreement with the previous studies.^[13] Hyperlipidemia in females may be attributed to the effects of sex hormones on body fat distribution, which leads to differences in altered lipoproteins.^[14] Another reason includes differences in coagulation, the pattern of obesity between men and women, and possible role for hyperinsulinemia.^[15] In our study reveals high prevalence of hypercholesterolemia, hypertriglyceridemia, high LDL and low HDL levels which are well known risk factors for CVD and abnormality of cholesterol metabolism may lead to heart attacks. Insulin affects the liver apolipoprotein production. It regulates the enzymatic activity of lipoprotein lipase and Cholesterol ester transport protein. All these factors are likely cause of dyslipidemia in Diabetes mellitus.^[16] Moreover, insulin deficiency reduces the activity of hepatic lipase and several steps in the production of biologically active lipoprotein lipase may be altered in DM.^[17] The main disorder in lipid metabolism was hypertriglyceridemia in our study. This finding is in concord with our previous study.^[18] In the study of Mahato RV et al, 54% diabetic individuals had elevated LDL and > 50% individuals had increased TG.^[19] These findings are similar to our study. But in contrast to our present study, they reported low HDL in 73% individuals. In our study, a highly significant correlation between HbA1c and Lipid profile which is similar with various previous studies.^[20] We also observed significant correlations between HbA1c and TC, LDL and HDL. In various studies, HbA1c level was eminent as showing positive correlation with TC, LDL and TG in diabetic patients.^[21] HDL was shown to be the stronger predictor of CVD in diabetic population by 'The Strong Heart Study' (data evaluated by Liu et al), with hazard ratios of 2.23 and 1.80 respectively in male and female.^[22] This study showed that increasing HDL cholesterol concentrations had significant, curvilinear relationships with CVD and CHD risk. Moreover, NCEP ATPIII has recommended using HDL cholesterol in assessing CVD risk in patients with diabetes. The measurement of HDL is simple which can be conducted even in non-fasting state of patients

and can be determined regardless of TG concentration. Hence, HDL cholesterol can be of great value in determining dyslipidaemia in diabetic subjects. Risk ratio showed the strongest correlation with HbA1c in our study. In the prospective cohort study with inclusion of 418 Type 2 diabetic individuals with follow-up until the appearance of a cardiovascular event, Reddy AS et al, showed that the main lipid predictor of vascular events was mean TC/HDL-C ratio with hazard ratio (HR) of 1.46. In the same study, the predictive power of the TC/HDL ratio was found to be higher than that of HDL cholesterol and study concluded that TC/HDL-C can be used as a treatment guides for diabetic dyslipidemia.^[23] Total number of apo-B containing particles and small LDL-C Particles are increased in diabetes and these metabolic abnormalities are better reflected by TC/HDL ratio and Non-HDL than LDL alone.^[24] Significant association of HbA1c with various lipid parameters such as TC, HDL, LDL in present study suggests the importance of glycaemic control in order to control dyslipidaemia

According to, Diabetes complications and control trial (DCCT) established HbA1c as the gold standard of glycaemic control. The level of HbA1c value $\leq 7.0\%$ was said to be appropriate for reducing the risk of cardiovascular complications.^[25] In the present study, we divided diabetic patients into 2 groups as per the HbA1c cutoff of 7.0%. The diabetic patients with HbA1c value $> 7.0\%$ exhibited a significant increase in TC, TG, LDL, VLDL and without any significant alteration in HDL in comparison to patients with HbA1c value $\leq 7.0\%$. According to Sultania HA et al showed the impact of glycaemic control on various lipid parameters in which the diabetic patients were categorized into 3 groups according to their HbA1c levels: group 1, good glycaemic control (HbA1c 6%–9%) and group 3, worst glycaemic control (HbA1c $> 9\%$). Poor and worst glycemic control is considered as risk factor for complications in diabetes. Strict glycaemic control lowers the risk of micro- and macrovascular complications of diabetes mellitus.^[26] Severity of dyslipidaemia increases in patients with higher HbA1c value. As elevated HbA1c and dyslipidaemia are independent risk factors of CVD, diabetic patients with elevated HbA1c and dyslipidaemia can be considered as a very high-risk group for CVD. Improving glycaemic control can substantially reduce the risk of cardiovascular events in diabetics.^[27] It has been estimated that reducing the HbA1c level by 0.2% could lower the mortality by 10%.^[28] According to Parveen et al. found a positive correlation between HbA1c and high triglycerides suggested that HbA1c can be used as a potent marker for dyslipidemia and mitigate the macro- and micro-vascular complications.^[29] In this study, a significant correlation was observed between levels of glycosylated hemoglobin (HbA1c) and lipid profile. This may in turn help in predicting the lipid profile levels from the degree of glycaemic control and therefore, identifying the patients with increased risk of diabetic complications. Lipid abnormalities are common in diabetic patients and frequently seen in patients with type-2 diabetic mellitus. The abnormal lipid profile observed in type 2 Diabetes mellitus is said to be related to insulin resistance as reported in previous studies, which leads to increased release of free fatty acids from fatty tissue, impaired insulin dependent muscle uptake of free fatty acids and increase fatty acid release to the hepatic tissue.^[30] It has been closely associated with diabetic dyslipidemia, hypertension and enormous risk to cardiovascular diseases. Chronic hyperglycemia causes glycation of apolipoproteins and interferes with the normal pathways of lipoprotein metabolism.^[31] It has been suggested that diabetes patients should join a fitness program and do regular exercise that comprises 30 mins of mild-intensity physical activity 4–6 times per week, with a minimum outlay of 200 Kcal. It is also suggested that every family physician be well aware of the relationship between HbA1c and hyperlipidemia in T2DM patients and check their patients' lipid profile and HbA1c at least twice a year to avoid future problems. There is a need for an educational program for diabetic patients regarding blood sugar control and the deleterious consequences of dyslipidemia. Awareness of this risk among family

physicians and T2DM patients can play a pivotal role in controlling and avoiding the grave consequences of this complication for T2DM patients. The strength of the study is that we had the complete biochemical data of the patients and we computed a comparison, a correlation and a regression analysis. The present study had a few limitations, including being a retrospective study as well as having too small of a sample size and the fact that patients' dietary habits, lifestyle patterns, time since diagnosis with DM and duration of regular physical activity were undetermined. The patients included in our study were all taking different antidiabetic medications. However, we could not analyze the data according to the treatment modalities, and it is possible that such a patient grouping would have some impact on the study results. We have not tested the effect of glycemic control on various lipid ratios as study of these ratios have proven to be useful as markers for insulin resistance and CVD risk in T2D patients.

Conclusion

In conclusion, HbA1c showed positive correlation with serum Total cholesterol and LDL, negative correlation with HDL. These findings suggest that HbA1c can also be used as predictor of dyslipidaemia in Type 2 Diabetics in addition to as a glycaemic control parameter. So, HbA1c may be utilized for screening diabetic patient for risk of cardiovascular events and also for timely intervention with lipid lowering drugs.

Reference

1. Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus: the expert committee on the diagnosis and classifications of diabetes mellitus. *Diabetes care*. 2003;26(11):3160.
2. Turner R, Holman R, Matthews D, Oakes S, Bassett P, Stratton I, et al. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. *Diabetologia*. 1991;34(12):877-90.
3. Diabetes, Fact sheet N 312. Available at <https://www.who.int/news-room/fact-sheets/detail/diabetes> Accessed on 08/06/2020.
4. American Diabetes Association. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. *Diabetes Care*. 2019;42(1):S13-S28.
5. Anjana RM, Pradeepa R, Deepa M, Mahanta J, Narain K, Das HK, et al. Prevalence of diabetes and prediabetes in 15 states of India: Results from the ICMR-INDIAB population-based cross-sectional study: methodological details. *Lancet Diabetes Endocrinol*. 2017;5(8):585-596.
6. Li Y, Zhao L, Yu D, Ding G (2018) The prevalence and risk factors of dyslipidemia in different diabetic progression stages among middle-aged and elderly populations in China. *PLoS ONE* 13(10): e0205709.
7. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. *Ann Intern Med* 2004; 14: 421-431.
8. Haffner SM, Lehto S, Ronnema T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *N Engl J Med* 1998; 339: 229-234.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) [special communication]. *JAMA* 2001; 285:2486-2497.
10. Florkowski C. HbA1c as a Diagnostic Test for Diabetes Mellitus - Reviewing the

- Evidence. *Clin Biochem Rev.* 2013;34(2):75–83.
11. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c: Slow glycosylation of hemoglobin in vivo. *J Clin Invest.* 1976;57(6):1652-1659.
 12. Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. *Biomark Insights.* 2016;11:95–104.
 13. Windler E. What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome? *Atheroscler Suppl* 2005;6: 11-14.
 14. Khaw KT, Wareham N, Bingham S, Luben R, Welch A and Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. *Ann Intern Med* 2004; 141: 413-420.
 15. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J Lipid Res* 1996; 37: 693-707.
 16. Tavangar K, Murata Y, Pedersen ME, Goers JF, Hoff-man AR, Kraemer FB. Regulation of lipoprotein lipase in the diabetic rat. *J Clin Invest* 1992; 90: 1672-1678.
 17. Regmi P, Gyawali P, Shrestha R, Sigdel M, Mehta KD, Majhi S. Pattern of Dyslipidemia in Type 2 Diabetic Subjects in Eastern Nepal. *JNAML* 2009; 10: 11-13.
 18. Sheth J, Shah A, Sheth F, Trivedi S, Nabar N, Shah N, et al. The association of dyslipidemia and obesity with glycated hemoglobin. *Clinical Diabet Endocrinol.* 2015;1(1):6. 34.
 19. Mahato RV, Gyawali P, Raut PS, Regmi P, Singh KP, Pandeya DR, et al. Association between glycaemic control and serum lipid profile in type 2 diabetic patients: Glycated haemoglobin as a dual biomarker. *Biomedical Research.* 2011;22(3):375- 80.
 20. Erciyas F, Taneli F, Arslan B, Uslu Y. Glycemic control, oxidative stress and lipid profile in children with type 1 Diabetes Mellitus. *Arch Med Res.* 2004; 35(2):134-40.
 21. Andersen GE, Christiansen JS, Mortensen HB, Christiansen KM, Pedersen-Bjerggaard L, Kastrup KW, et al. Plasma lipid and lipoprotein in type 1 diabetic children and adolescent in relation to metabolic regulation, obesity and genetic hyperlipoproteinemia. *Acta Paediatr Scand.* 1983;72:361-5.
 22. Liu Y, Huang H. Association of glycosylated hemoglobin level with lipid ratio and individual lipids in type 2 diabetic patients. *Asian Pacific J Trop Med.* 2012;5(6):469-71.
 23. Reddy AS, Meera S, Ebenezer W. Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indicator of dyslipidemia. *Asian J Pharm Clin Res.* 2014;7:153- 5.
 24. Ohta T, Nishiyama S, Nakamura T, Saku K, Maung KK, Matsuda I. Predominance of large low density lipoprotein particles and lower fractional esterification rate of cholesterol in high density lipoprotein in children with insulin-dependent diabetes mellitus. *Eur J Pediatr.* 1998;157:276-81.
 25. DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the diabetes control and complications trial. *Diabetes* 1996;45(10):1289-98.
 26. Sultania S, Thakur D, Kulshreshtha M. Study of lipid profile in type 2 diabetes mellitus patients and its correlation with HbA1c. *Int J Contemp Med Res.* 2017;4(2):437-9.
 27. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. *Nat Clin Pract Endocrinol Metab.* 2009;5(3):150-9.
 28. Parveen K, Siddiqui WA, Kausara MA, Kuddusa M, Syed Monowar AS. Diabetic nephropathy - a major macrovascular complication. *Int J Pharmaceuti Res Allied Sci.* 2016;5:132-58.
 29. Gantala SR, Kummari R, Tupurani MA, Galimudi RK, Gundapaneni KK, Kupsal K, et al.

- Evaluation of Glycemic, Lipid, Immune-Inflammatory and Oxidative Stress Markers in Various Clinical Stages of Type 2 Diabetic Nephropathy. *J Metabolic Synd* 2018;7: 237.
30. Thambiah SC, Samsudin IN, George E, ZahariSham SY, Lee HM, Muhamad MA, et al. Relationship between dyslipidaemia and glycaemic status in patients with type 2 diabetes mellitus. *Malaysian J Pathol*. 2016;38(2):123-30.
 31. Avogaro A, Giorda C, Maggini M, Mannucci E, Raschetti R, Lombardo F, et al. Incidence of coronary heart disease in type 2 diabetic men and women: impact of microvascular complications, treatment and geographic location. *Diabetes Care*. 2007;30(5):1241-7.